Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, and its news flow reflects this GI specialization. Company updates frequently center on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) that Phathom markets in the United States for adult patients with Erosive GERD, Non-Erosive GERD, and Helicobacter pylori infection in combination regimens.
Investors and healthcare observers following PHAT news can expect regular announcements on commercial performance, including prescription milestones and revenue updates tied to VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Phathom’s press releases have highlighted metrics such as total VOQUEZNA prescriptions dispensed in the United States and quarterly financial results, often accompanied by commentary on commercialization strategy and expense trends.
Another major category of Phathom news involves clinical and scientific developments. The company reports progress in trials like the Phase 3 pHalcon-NERD-301 study in Non-Erosive GERD and the Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA in eosinophilic esophagitis. Publications in peer-reviewed journals and presentations at gastroenterology conferences, such as the American College of Gastroenterology Annual Scientific Meeting, are common topics in its releases.
Phathom also issues news on capital markets activity, including proposed and priced underwritten public offerings of common stock and pre-funded warrants, as well as corporate updates such as leadership appointments and participation in investor conferences. Together, these news items provide a view into the company’s GI-focused strategy, clinical pipeline, commercial trajectory, and financing plans. For users tracking PHAT, the news page offers a consolidated stream of these developments over time.
Phathom Pharmaceuticals (Nasdaq: PHAT) said members of its management team will participate in two investor conferences in April 2026: the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026 and the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026.
Management will hold one-on-one meetings and a Needham fireside chat at 1:30 pm EDT; webcasts and recordings will be available via the company website for 90 days.
H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.
Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q4 2025 net revenue of $57.6M and full-year 2025 net revenue of $175.1M, a 217% increase versus 2024. The company completed a ~$130M equity offering, modified term debt (remaining principal ~$175M) and expects operating profitability beginning in Q3 2026.
Phathom reported FY 2025 net loss of $221.2M, cash and cash equivalents of $130.0M as of Dec 31, 2025, and provided 2026 guidance: net revenues $320–$345M, gross margin ~80%, and non-GAAP opex $235–$250M.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced management will attend three investor conferences in March 2026: TD Cowen (Boston) on March 2, Jefferies Biotech on the Beach (Miami) on March 10, and Barclays Global Healthcare (Miami) on March 11.
The company will host a March 2 presentation at 10:30 am EST and a March 11 fireside chat at 3:30 pm EDT, and management will hold one-on-one meetings. Webcasts and archived recordings will be available on the investor News & Events page and remain accessible for 90 days.
Phathom Pharmaceuticals (Nasdaq: PHAT) will report fourth quarter and full year 2025 financial results and provide a business update via live webcast on Thursday, February 26, 2026 at 8:00 am EST.
Investors and media can access the live webcast and related materials on Phathom's Events & Presentations page; a recording will be available for 90 days after the call.
Phathom Pharmaceuticals (Nasdaq: PHAT) will present at the Guggenheim Emerging Outlook Biotech Summit 2026. A management team fireside chat is scheduled for Thursday, February 12, 2026 at 11:30 am ET, with one-on-one meetings during the February 11-12 conference in New York.
Investors can access a live webcast and archived recording via the company website; recordings will remain available for 90 days after the event.
Phathom Pharmaceuticals (Nasdaq: PHAT) priced an underwritten public offering of 6,875,000 common shares and pre-funded warrants to purchase 1,250,078 shares at $16.00 per common share and $15.999 per pre-funded warrant, generating approximately $130 million in gross proceeds before fees.
The underwriters have a 30-day option to buy up to 1,218,761 additional shares. The offering is expected to close on or about January 9, 2026, subject to customary closing conditions. Proceeds are intended for general corporate purposes, including working capital, commercialization, and R&D.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced a proposed underwritten public offering of common stock and, for some investors, pre-funded warrants, with underwriters granted a 30-day option to buy up to an additional 15% of the securities. The company said net proceeds are intended for general corporate purposes, including working capital, commercialization, and R&D. The offering is being made from a shelf registration that became effective on January 7, 2026. Guggenheim Securities and Cantor are joint bookrunning managers. There is no assurance the offering will be completed or on stated terms.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported preliminary unaudited results for Q4 and full-year 2025. For Q4 2025, the company expects net revenues ~$57–58M, GAAP operating expenses of $59–61M, non-GAAP operating expenses of $51–53M (excludes ~$8M stock-based compensation), and net cash usage ~ $6M. Cash and cash equivalents were ~$130M at Dec 31, 2025. For full-year 2025, expected net revenues ~$174.5–175.5M, GAAP operating expenses $315.5–317.5M, and non-GAAP operating expenses $284.5–286.5M (excludes ~$31M stock-based compensation). VOQUEZNA surpassed 1 million U.S. prescriptions since launch. Operating profitability is anticipated in H2 2026 (ex-stock compensation). Results are preliminary and unaudited.
Phathom Pharmaceuticals (NASDAQ: PHAT) announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA® (vonoprazan) 20 mg as an investigational oral treatment for eosinophilic esophagitis (EoE) in adults.
The randomized, double-blind, placebo-controlled study will enroll ~80 adults with endoscopic-confirmed EoE and dysphagia across ~40 U.S. sites, with Part 1 consisting of 12 weeks of VOQUEZNA or placebo and an optional 12-week extension (Part 2) where all subjects receive VOQUEZNA. Topline primary and secondary results are anticipated in 2027. The company said positive data could support discussions on a pediatric program and potentially extend regulatory exclusivity.